Cargando…
Gut Microbiota and Bile Acids Mediate the Clinical Benefits of YH1 in Male Patients with Type 2 Diabetes Mellitus: A Pilot Observational Study
Our previous clinical trial showed that a novel concentrated herbal extract formula, YH1 (Rhizoma coptidis and Shen-Ling-Bai-Zhu-San), improved blood glucose and lipid control. This pilot observational study investigated whether YH1 affects microbiota, plasma, and fecal bile acid (BA) compositions i...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9505101/ https://www.ncbi.nlm.nih.gov/pubmed/36145605 http://dx.doi.org/10.3390/pharmaceutics14091857 |
_version_ | 1784796388299636736 |
---|---|
author | Huang, Yueh-Hsiang Wu, Yi-Hong Tang, Hsiang-Yu Chen, Szu-Tah Wang, Chih-Ching Ho, Wan-Jing Lin, Yi-Hsuan Liu, Geng-Hao Lin, Pei-Yeh Lo, Chi-Jen Yeh, Yuan-Ming Cheng, Mei-Ling |
author_facet | Huang, Yueh-Hsiang Wu, Yi-Hong Tang, Hsiang-Yu Chen, Szu-Tah Wang, Chih-Ching Ho, Wan-Jing Lin, Yi-Hsuan Liu, Geng-Hao Lin, Pei-Yeh Lo, Chi-Jen Yeh, Yuan-Ming Cheng, Mei-Ling |
author_sort | Huang, Yueh-Hsiang |
collection | PubMed |
description | Our previous clinical trial showed that a novel concentrated herbal extract formula, YH1 (Rhizoma coptidis and Shen-Ling-Bai-Zhu-San), improved blood glucose and lipid control. This pilot observational study investigated whether YH1 affects microbiota, plasma, and fecal bile acid (BA) compositions in ten untreated male patients with type 2 diabetes (T2D), hyperlipidemia, and a body mass index ≥ 23 kg/m(2). Stool and plasma samples were collected for microbiome, BA, and biochemical analyses before and after 4 weeks of YH1 therapy. As previous studies found, the glycated albumin, 2-h postprandial glucose, triglycerides, total cholesterol, and low-density lipoprotein cholesterol levels were significantly improved after YH1 treatment. Gut microbiota revealed an increased abundance of the short-chain fatty acid-producing bacteria Anaerostipes and Escherichia/Shigella. Furthermore, YH1 inhibited specific phylotypes of bile salt hydrolase-expressing bacteria, including Parabacteroides, Bifidobacterium, and Bacteroides caccae. Stool tauro-conjugated BA levels increased after YH1 treatment. Plasma total BAs and 7α-hydroxy-4-cholesten-3-one (C4), a BA synthesis indicator, were elevated. The reduced deconjugation of BAs and increased plasma conjugated BAs, especially tauro-conjugated BAs, led to a decreased glyco- to tauro-conjugated BA ratio and reduced unconjugated secondary BAs. These results suggest that YH1 ameliorates T2D and hyperlipidemia by modulating microbiota constituents that alter fecal and plasma BA compositions and promote liver cholesterol-to-BA conversion and glucose homeostasis. |
format | Online Article Text |
id | pubmed-9505101 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-95051012022-09-24 Gut Microbiota and Bile Acids Mediate the Clinical Benefits of YH1 in Male Patients with Type 2 Diabetes Mellitus: A Pilot Observational Study Huang, Yueh-Hsiang Wu, Yi-Hong Tang, Hsiang-Yu Chen, Szu-Tah Wang, Chih-Ching Ho, Wan-Jing Lin, Yi-Hsuan Liu, Geng-Hao Lin, Pei-Yeh Lo, Chi-Jen Yeh, Yuan-Ming Cheng, Mei-Ling Pharmaceutics Article Our previous clinical trial showed that a novel concentrated herbal extract formula, YH1 (Rhizoma coptidis and Shen-Ling-Bai-Zhu-San), improved blood glucose and lipid control. This pilot observational study investigated whether YH1 affects microbiota, plasma, and fecal bile acid (BA) compositions in ten untreated male patients with type 2 diabetes (T2D), hyperlipidemia, and a body mass index ≥ 23 kg/m(2). Stool and plasma samples were collected for microbiome, BA, and biochemical analyses before and after 4 weeks of YH1 therapy. As previous studies found, the glycated albumin, 2-h postprandial glucose, triglycerides, total cholesterol, and low-density lipoprotein cholesterol levels were significantly improved after YH1 treatment. Gut microbiota revealed an increased abundance of the short-chain fatty acid-producing bacteria Anaerostipes and Escherichia/Shigella. Furthermore, YH1 inhibited specific phylotypes of bile salt hydrolase-expressing bacteria, including Parabacteroides, Bifidobacterium, and Bacteroides caccae. Stool tauro-conjugated BA levels increased after YH1 treatment. Plasma total BAs and 7α-hydroxy-4-cholesten-3-one (C4), a BA synthesis indicator, were elevated. The reduced deconjugation of BAs and increased plasma conjugated BAs, especially tauro-conjugated BAs, led to a decreased glyco- to tauro-conjugated BA ratio and reduced unconjugated secondary BAs. These results suggest that YH1 ameliorates T2D and hyperlipidemia by modulating microbiota constituents that alter fecal and plasma BA compositions and promote liver cholesterol-to-BA conversion and glucose homeostasis. MDPI 2022-09-02 /pmc/articles/PMC9505101/ /pubmed/36145605 http://dx.doi.org/10.3390/pharmaceutics14091857 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Huang, Yueh-Hsiang Wu, Yi-Hong Tang, Hsiang-Yu Chen, Szu-Tah Wang, Chih-Ching Ho, Wan-Jing Lin, Yi-Hsuan Liu, Geng-Hao Lin, Pei-Yeh Lo, Chi-Jen Yeh, Yuan-Ming Cheng, Mei-Ling Gut Microbiota and Bile Acids Mediate the Clinical Benefits of YH1 in Male Patients with Type 2 Diabetes Mellitus: A Pilot Observational Study |
title | Gut Microbiota and Bile Acids Mediate the Clinical Benefits of YH1 in Male Patients with Type 2 Diabetes Mellitus: A Pilot Observational Study |
title_full | Gut Microbiota and Bile Acids Mediate the Clinical Benefits of YH1 in Male Patients with Type 2 Diabetes Mellitus: A Pilot Observational Study |
title_fullStr | Gut Microbiota and Bile Acids Mediate the Clinical Benefits of YH1 in Male Patients with Type 2 Diabetes Mellitus: A Pilot Observational Study |
title_full_unstemmed | Gut Microbiota and Bile Acids Mediate the Clinical Benefits of YH1 in Male Patients with Type 2 Diabetes Mellitus: A Pilot Observational Study |
title_short | Gut Microbiota and Bile Acids Mediate the Clinical Benefits of YH1 in Male Patients with Type 2 Diabetes Mellitus: A Pilot Observational Study |
title_sort | gut microbiota and bile acids mediate the clinical benefits of yh1 in male patients with type 2 diabetes mellitus: a pilot observational study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9505101/ https://www.ncbi.nlm.nih.gov/pubmed/36145605 http://dx.doi.org/10.3390/pharmaceutics14091857 |
work_keys_str_mv | AT huangyuehhsiang gutmicrobiotaandbileacidsmediatetheclinicalbenefitsofyh1inmalepatientswithtype2diabetesmellitusapilotobservationalstudy AT wuyihong gutmicrobiotaandbileacidsmediatetheclinicalbenefitsofyh1inmalepatientswithtype2diabetesmellitusapilotobservationalstudy AT tanghsiangyu gutmicrobiotaandbileacidsmediatetheclinicalbenefitsofyh1inmalepatientswithtype2diabetesmellitusapilotobservationalstudy AT chenszutah gutmicrobiotaandbileacidsmediatetheclinicalbenefitsofyh1inmalepatientswithtype2diabetesmellitusapilotobservationalstudy AT wangchihching gutmicrobiotaandbileacidsmediatetheclinicalbenefitsofyh1inmalepatientswithtype2diabetesmellitusapilotobservationalstudy AT howanjing gutmicrobiotaandbileacidsmediatetheclinicalbenefitsofyh1inmalepatientswithtype2diabetesmellitusapilotobservationalstudy AT linyihsuan gutmicrobiotaandbileacidsmediatetheclinicalbenefitsofyh1inmalepatientswithtype2diabetesmellitusapilotobservationalstudy AT liugenghao gutmicrobiotaandbileacidsmediatetheclinicalbenefitsofyh1inmalepatientswithtype2diabetesmellitusapilotobservationalstudy AT linpeiyeh gutmicrobiotaandbileacidsmediatetheclinicalbenefitsofyh1inmalepatientswithtype2diabetesmellitusapilotobservationalstudy AT lochijen gutmicrobiotaandbileacidsmediatetheclinicalbenefitsofyh1inmalepatientswithtype2diabetesmellitusapilotobservationalstudy AT yehyuanming gutmicrobiotaandbileacidsmediatetheclinicalbenefitsofyh1inmalepatientswithtype2diabetesmellitusapilotobservationalstudy AT chengmeiling gutmicrobiotaandbileacidsmediatetheclinicalbenefitsofyh1inmalepatientswithtype2diabetesmellitusapilotobservationalstudy |